China Issues New Guidelines On Phase I Trials – Will It Speed Up Approvals?
This article was originally published in PharmAsia News
Executive Summary
The clinical trial process has become a bottleneck for licensing new drugs in China. Now, China’s State FDA has stepped up with a new guideline for Phase I clinical trials– will it help speed up the process?